

MODELLING SYMPTOM PROPAGATION IN PATHOGENS INFECTING VIA THE RESPIRATORY TRACT

Ed Hill

Civic Health Innovation Labs (CHIL), University of Liverpool


Member of JUNIPER Partnership (Joint Universities Pandemic & Epidemiological Research)


Lead author: Phoebe Asplin (University of Warwick)

Co-supervisors: Matt Keeling (University of Warwick), Rebecca Mancy (University of Glasgow)

External partners: Tom Finnie (UKHSA), Fergus Cumming (FCDO)










What is symptom propagation?

Symptom propagation occurs when the symptom set of an infected individual depends on the symptom set of the individual from which they acquired infection



Biological background



Study aims

1. Pathogens with symptom propagation traits

What is the evidence (supporting and non-supporting) for different pathogens infecting via the respiratory tract for the presence of symptom propagation mechanisms?

2. Modelling symptom propagation

How can we include symptom propagation in models of infectious disease transmission?

3. Modelling interventions

How does symptom propagation affect isolation & vaccination strategies?



Modelling paper



Literature review

1. Pathogens with symptom propagation traits

What is the evidence (supporting and non-supporting) for different pathogens infecting via the respiratory tract for the presence of symptom propagation mechanisms?

Dose-severity relationships

Coronaviruses

SARS-CoV-2		24, 3, 4
MERS-CoV		7, 0, 0
SARS-CoV-1		7, 0, 0

Viruses that cause influenza-like illness

Influenza virus		22, 1, 3
RSV		12, 1, 8
Rhinovirus		7, 1, 7
Adenovirus		5, 0, 1

Viruses that cause pox-like illness

Measles virus		14, 0, 0
Variola virus		1, 0, 1
VZV		2, 1, 0

Bacteria

M. tuberculosis		12, 1, 0
Y. pestis		1, 0, 2
B. pertussis		4, 0, 0
GAS		2, 0, 1

Pathogen non-specific

Route-severity relationships

Coronaviruses

SARS-CoV-2		5, 0, 1
MERS-CoV		3, 0, 5
SARS-CoV-1		0, 0, 0

Viruses that cause influenza-like illness

Influenza virus		10, 0, 0
RSV		2, 0, 4
Rhinovirus		0, 0, 0
Adenovirus		3, 0, 0

Viruses that cause pox-like illness

Measles virus		0, 0, 3
Variola virus		4, 0, 0
VZV		0, 0, 0

Bacteria

M. tuberculosis		3, 0, 4
Y. pestis		10, 0, 0
B. pertussis		2, 0, 0
GAS		2, 0, 0

Pathogen non-specific




Literature review



Literature review

Dose-severity relationships for Influenza



OPEN ACCESS PEER-REVIEWED

RESEARCH ARTICLE

Clinical correlation of influenza and respiratory syncytial virus load measured by digital PCR

Diego R. Hijano , Jessica Brazelton de Cardenas , Gabriela Maron, Cherilyn D. Garner, Jose A. Ferrolino, Ronald H. Dallas, Zhengming Gu, Randall T. Hayden

Published: September 3, 2019 • <https://doi.org/10.1371/journal.pone.0220908>



Literature review



OPEN ACCESS PEER-REVIEWED

RESEARCH ARTICLE

Exhaled Aerosol Transmission of Pandemic and Seasonal H1N1 Influenza Viruses in the Ferret

Frederick Koster , Kristine Gouveia, Yue Zhou, Kristin Lowery, Robert Russell, Heather MacInnes, Zemmie Pollock, R. Colby Layton, Jennifer Cromwell, Denise Toleno, John Pyle, Michael Zubelewicz, Kevin Harrod, [...], Yung-Sung Cheng
[view all]

Published: April 3, 2012 • <https://doi.org/10.1371/journal.pone.0033118>



Literature review



RESEARCH ARTICLE | BIOLOGICAL SCIENCES | 8



Infectious virus in exhaled breath of symptomatic seasonal influenza cases from a college community

Jing Yan, Michael Grantham, Jovan Pantelic, +5, and EMIT Consortium [Authors Info & Affiliations](#)


Edited by Peter Palese, Icahn School of Medicine at Mount Sinai, New York, NY, and approved December 15, 2017 (received for review September 19, 2017)

January 18, 2018 | 115 (5) 1081-1086 | <https://doi.org/10.1073/pnas.1716561115>



Literature review

Dose-severity relationships for Influenza



JOURNAL ARTICLE

A Dose-finding Study of a Wild-type Influenza A(H3N2) Virus in a Healthy Volunteer Human Challenge Model

Alison Han , Lindsay M Czajkowski, Amanda Donaldson, Holly Ann Baus, Susan M Reed, Rani S Athota, Tyler Bristol, Luz Angela Rosas, Adriana Cervantes-Medina, Jeffery K Taubenberger ... Show more

Clinical Infectious Diseases, Volume 69, Issue 12, 15 December 2019, Pages 2082–2090,
<https://doi.org/10.1093/cid/ciz141>

Published: 16 February 2019 Article history ▾



Literature review

Route-severity relationships for Influenza



JOURNAL ARTICLE

Exposure to Influenza Virus Aerosols During Routine Patient Care FREE

Werner E. Bischoff , Katrina Swett, Iris Leng, Timothy R. Peters Author Notes

The Journal of Infectious Diseases, Volume 207, Issue 7, 1 April 2013, Pages 1037–1046,
<https://doi.org/10.1093/infdis/jis773>

Published: 30 January 2013 Article history ▾



Literature review

Route-severity relationships for Influenza



Restricted access | Research article | First published July 1966

Human Influenza Resulting from Aerosol Inhalation

[Robert H. Alford](#), [Julius A. Kasel](#), [Peter J. Gerone](#), and [Vernon Knight](#) -1 [View all authors and affiliations](#)

[Volume 122, Issue 3](#) | <https://doi.org/10.3181/00379727-122-31255>



Literature review

Dose-severity relationships for SARS-CoV-2



On the SARS-CoV-2 "Variolation Hypothesis": No Association Between Viral Load of Index Cases and COVID-19 Severity of Secondary Cases

Mattia Trunfio^{1*} Bianca Maria Longo¹ Francesca Alladio¹ Francesco Venuti¹
Francesco Cerutti² Valeria Ghisetti² Stefano Bonora¹ Giovanni Di Perri¹
Andrea Calcagno¹



Literature review

Route-severity relationships for SARS-CoV-2



Articles

Viral emissions into the air and environment after SARS-CoV-2 human challenge: a phase 1, open label, first-in-human study

Jie Zhou PhD^a †, Anika Singanayagam PhD^b †, Niluka Goonawardane PhD^a, Maya Moshe MSc^a,
Fiachra P Sweeney MSc^a, Ksenia Sukhova MSc^a, Ben Killingley MD^d, Mariya Kalinova MD^e,
Alex J Mann MSc^e, Andrew P Catchpole DPhil^e, Prof Michael R Barer PhD^f,
Prof Neil M Ferguson DPhil^c, Prof Christopher Chiu PhD^b, Prof Wendy S Barclay PhD^a  



Literature review

Scoping literature review: Conclusions

- The **relationship between severity, LRT infection and aerosol transmission** provide support for the idea that both mechanisms of symptom propagation can act for some pathogens (e.g. influenza).
- Symptom propagation is highly **pathogen specific**.
- Further studies **investigating LRT viral load** would be helpful to confirm the role of dose-severity relationships with LRT involvement.
- Work required to **quantify the epidemiological impact** of symptom propagation and its strength.


2. Modelling symptom propagation

How can we include symptom propagation in models of infectious disease transmission?



Modelling symptom propagation

Modelling paper





Modelling paper

Model equations

$$S \quad \boxed{\frac{dS}{dt} = -\lambda_M S - \lambda_S S}$$

$$E \quad \boxed{\frac{dE_M}{dt} = (\alpha + (1 - \alpha)(1 - \nu))\lambda_M S + (1 - \alpha)(1 - \nu)\lambda_S S - \epsilon E_M}$$

$$\boxed{\frac{dE_S}{dt} = (1 - \alpha)\nu\lambda_M S + (\alpha + (1 - \alpha)\nu)\lambda_S S - \epsilon E_S}$$

$$I \quad \boxed{\frac{dI_M}{dt} = \epsilon E_M - \gamma_M I_M}$$

$$\boxed{\frac{dI_S}{dt} = \epsilon E_S - \gamma_S I_S}$$

$$R \quad \boxed{\frac{dR_M}{dt} = \gamma_M I_M}$$

$$\boxed{\frac{dR_S}{dt} = \gamma_S I_S}$$

$$\lambda_M = \frac{\beta_M I_M}{N}$$

$$\lambda_S = \frac{\beta_S I_S}{N}$$

Expectations about epidemiological impacts

- 01 Larger proportion of infections should be severe
- 02 Potential to under- or overestimate intervention effectiveness
- 03 Could mean that we choose the wrong intervention strategy




Modelling paper

R_0 analysis

- We consider two disease parameterisations:
seasonal influenza ($R_0 = 1.5$ when $\alpha = 0$); pandemic influenza ($R_0 = 3.0$).

Since R_0 increases with α , these parameterisations are not realistic for stronger symptom propagation.







Modelling paper

Final outbreak size

When we fix R_0 the final outbreak size is constant across values of α .

The proportion of cases that are severe also increases.






Modelling paper

The proportion of cases that are severe, P

- If $\gamma_S = \gamma_M$, then the proportion of cases that are severe tends to a fixed value (shown by the red dashed lines).

P reaches the fixed value within 80 days for all strengths of symptom propagation.






Modelling paper

The proportion of cases that are severe, P

- If $\gamma_S = \gamma_M$, then the proportion of cases that are severe tends to a fixed value (shown by the red dashed lines).

P reaches the fixed value by the time 1% of cases have occurred for all strengths of symptom propagation.






The proportion of cases that are severe, P

- If $\gamma_S \neq \gamma_M$, then the proportion of cases that are severe varies over time.

P reaches a plateau in the early stages of the outbreak and then increases to a higher plateau in the late stages.



3. Modelling interventions

How does symptom propagation affect isolation strategies?



Literature review

Isolation scenarios

We compared between two isolation strategies:

1. Isolating **mild AND severely infected** individuals
2. Isolating **only severely infected** individuals



For each strategy, the probability of an infected individual eligible for isolation being successfully isolated was **0.5**.



Literature review

Isolation case-study

- Red regions: isolating mild+severe cases leads to an overall increase in case numbers




3. Modelling interventions

How does symptom propagation affect the effectiveness of vaccination strategies?



Modelling symptom propagation


Modelling paper





Symptom-attenuating vaccine (SA)


Modelling paper





Modelling paper

Infection-blocking vaccine (IB)



Exploring the effect of varying α on the proportion of the population infected


Final proportion of the population in each disease status compartment for α : 0.2 (hashed) and 0.8 (solid)

SA vaccines are more effective when symptom propagation is stronger.

For pandemic influenza and high uptake, which of SA and IB is more effective at reducing severe cases depends on α .

Which intervention is preferable can depend on whether you care about reducing all cases or only severe cases.

Modelling paper



Symptom-attenuating versus infection-blocking vaccines

Modelling paper




Blue regions denote parameter values for which IB vaccines are more impactful (in reducing severe cases).

Red regions denote parameter values for which SA vaccines are more impactful (in reducing severe cases).

For low uptake (top row), which vaccine is more effective only depends on the disease parameterisation.

For high uptake and pandemic influenza, which vaccine is more effective depends on α .





Modelling paper

Modelling study: Conclusions

- Modelling shows that symptom propagation can affect **epidemiological outcomes**:
 - The total number of cases
 - The proportion of cases that are severe
- Under strong symptom propagation, interventions that **reduce symptom severity** are **more effective** at reducing total and severe cases.
- The **strength of symptom propagation** has the potential to determine the most effective **intervention type**.

Future work

Future work will be increasingly **computational** and will focus on:

- **Parameter inference:** Inferring the value of α from data to quantify the extent of symptom propagation.
 - Synthetic data studies
 - Real-world application to individual-level data for SARS-CoV-2
- **Structured populations:** Epidemiological modelling to investigate
 - e.g. implications of clustering of severe cases
 - e.g. stochastic simulations on a network

Acknowledgements

Lead author: Phoebe Asplin
(University of Warwick)

My co-supervisors: Matt Keeling
(University of Warwick), Rebecca
Mancy (University of Glasgow)

External partners: Tom Finnie
(UKHSA) & Fergus Cumming (FCDO).



Literature review

INTERFACE

royalsocietypublishing.org/journal/rsif



Review



Cite this article: Aspin P, Mancy R, Finnie T, Cumming F, Keeling MJ, Hill EM. 2024

Symptom propagation in respiratory pathogens of public health concern: a review of the evidence. *J. R. Soc. Interface* 21: 2024009.
<https://doi.org/10.1098/rsif.2024.0009>

Symptom propagation in respiratory pathogens of public health concern:
a review of the evidence

Phoebe Asplin^{1,2,3}, Rebecca Mancy^{5,6}, Thomas Finnie⁷, Fergus Cumming⁸,
Matt J. Keeling^{2,3,4} and Edward M. Hill^{2,3}

¹EPSRC & MRC Centre for Doctoral Training in Mathematics for Real-World Systems, ²Mathematics Institute, and
³The Zeeman Institute for Systems Biology & Infectious Disease Epidemiology Research, University of Warwick,
Coventry, UK

⁴School of Life Sciences, ⁵School of Biodiversity, One Health and Veterinary Medicine, and ⁶MRC/CSO Social and
Public Health Sciences Unit, University of Glasgow, Glasgow, UK

⁷Data, Analytics and Surveillance, UK Health Security Agency, London, UK

⁸Foreign, Commonwealth and Development Office, London, UK



Modelling paper

PLOS COMPUTATIONAL BIOLOGY

RESEARCH ARTICLE

Epidemiological and health economic
implications of symptom propagation in
respiratory pathogens: A mathematical
modelling investigation

Phoebe Asplin^{1,2,3*}, Matt J. Keeling^{2,3,4}, Rebecca Mancy^{5,6}, Edward M. Hill^{2,3*}

¹EPSRC & MRC Centre for Doctoral Training in Mathematics for Real-World Systems, University of
Warwick, Coventry, United Kingdom, ²Mathematics Institute, University of Warwick, Coventry, United
Kingdom, ³The Zeeman Institute for Systems Biology & Infectious Disease Epidemiology Research,
University of Warwick, Coventry, United Kingdom, ⁴School of Life Sciences, University of Warwick, Coventry,
United Kingdom, ⁵School of Biodiversity, One Health and Veterinary Medicine, University of Glasgow,
Glasgow, United Kingdom, ⁶MRC/CSO Social and Public Health Sciences Unit, University of Glasgow,
Glasgow, United Kingdom

* P.Asplin@warwick.ac.uk (PA); Edward.Hill@warwick.ac.uk (EMH)

This research was supported by the
Engineering and Physical Sciences Research
Council through the MathSys CDT.



Engineering and
Physical Sciences
Research Council